SQTL3
MCID: SMK004
MIFTS: 44

Smoking As a Quantitative Trait Locus 3 (SQTL3)

Categories: Cancer diseases, Genetic diseases, Respiratory diseases

Aliases & Classifications for Smoking As a Quantitative Trait Locus 3

MalaCards integrated aliases for Smoking As a Quantitative Trait Locus 3:

Name: Smoking As a Quantitative Trait Locus 3 57 29 6
Lung Cancer Susceptibility 2 57 13 6 70
Nicotine Dependence 57 70
Nicotine Dependence, Susceptibility to 57
Sqtl3 57

Classifications:



External Ids:

OMIM® 57 612052
UMLS 70 C0028043 C2677571

Summaries for Smoking As a Quantitative Trait Locus 3

MalaCards based summary : Smoking As a Quantitative Trait Locus 3, also known as lung cancer susceptibility 2, is related to tobacco addiction and alcohol dependence. An important gene associated with Smoking As a Quantitative Trait Locus 3 is CHRNA3 (Cholinergic Receptor Nicotinic Alpha 3 Subunit), and among its related pathways/superpathways are Transmission across Chemical Synapses and Nicotine Pathway (Dopaminergic Neuron), Pharmacodynamics. The drugs Naltrexone and Oxytocin have been mentioned in the context of this disorder. Affiliated tissues include lung, cortex and skin, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

More information from OMIM: 612052

Related Diseases for Smoking As a Quantitative Trait Locus 3

Diseases in the Smoking As a Quantitative Trait Locus 3 family:

Smoking As a Quantitative Trait Locus 1 Smoking As a Quantitative Trait Locus 2

Diseases related to Smoking As a Quantitative Trait Locus 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 tobacco addiction 32.2 CHRNA5 CHRNA3
2 alcohol dependence 30.4 CHRNA5 CHRNA3
3 substance dependence 30.3 CHRNA5 CHRNA3
4 cocaine dependence 29.8 CHRNA5 CHRNA3
5 drug dependence 10.6
6 anxiety 10.6
7 alcohol use disorder 10.6
8 depression 10.6
9 mood disorder 10.5
10 substance abuse 10.5
11 mental depression 10.5
12 schizophrenia 10.5
13 attention deficit-hyperactivity disorder 10.5
14 withdrawal disorder 10.5
15 post-traumatic stress disorder 10.5
16 major depressive disorder 10.5
17 personality disorder 10.5
18 major affective disorder 8 10.4
19 major affective disorder 9 10.4
20 bipolar disorder 10.4
21 conduct disorder 10.3
22 antisocial personality disorder 10.3
23 panic disorder 10.3
24 severe combined immunodeficiency 10.3
25 lung cancer 10.3
26 avoidant personality disorder 10.3
27 opiate dependence 10.3
28 lung disease 10.3
29 pulmonary disease, chronic obstructive 10.2
30 pathological gambling 10.2
31 psychotic disorder 10.2
32 eating disorder 10.2
33 cannabis dependence 10.2
34 cannabis abuse 10.2
35 peripheral vascular disease 10.1
36 social phobia 10.1
37 vascular disease 10.1
38 schizoaffective disorder 10.1
39 48,xyyy 10.1
40 pancreatic cancer 10.0
41 anorexia nervosa 10.0
42 phobia, specific 10.0
43 smoking as a quantitative trait locus 1 10.0
44 angina pectoris 10.0
45 alexithymia 10.0
46 pain agnosia 10.0
47 dysthymic disorder 10.0
48 somatization disorder 10.0
49 generalized anxiety disorder 10.0
50 disease of mental health 10.0

Graphical network of the top 20 diseases related to Smoking As a Quantitative Trait Locus 3:



Diseases related to Smoking As a Quantitative Trait Locus 3

Symptoms & Phenotypes for Smoking As a Quantitative Trait Locus 3

Clinical features from OMIM®:

612052 (Updated 05-Apr-2021)

GenomeRNAi Phenotypes related to Smoking As a Quantitative Trait Locus 3 according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-121 9.28 CHRNA3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.28 CHRNA3
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.28 CHRNA5
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.28 CHRNA3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.28 CHRNA5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-35 9.28 CHRNA3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.28 CHRNA3 CHRNA5
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.28 CHRNA5

Drugs & Therapeutics for Smoking As a Quantitative Trait Locus 3

Drugs for Smoking As a Quantitative Trait Locus 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
2
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
6
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
7
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
8
Ethanol Approved Phase 4 64-17-5 702
9
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
10 Narcotics Phase 4
11 Narcotic Antagonists Phase 4
12 Progestins Phase 4
13 Central Nervous System Stimulants Phase 4
14 Psychotropic Drugs Phase 4
15 Antidepressive Agents Phase 4
16 Cytochrome P-450 Enzyme Inhibitors Phase 4
17 Dopamine Agents Phase 4
18 Dopamine Uptake Inhibitors Phase 4
19 Hypnotics and Sedatives Phase 4
20
Carbon monoxide Approved, Investigational Phase 3 630-08-0 281
21
Propranolol Approved, Investigational Phase 3 525-66-6 4946
22
Mineral oil Approved, Vet_approved Phase 3 8042-47-5
23 Dermatologic Agents Phase 3
24 Vasodilator Agents Phase 3
25 Antihypertensive Agents Phase 3
26 Adrenergic Agents Phase 3
27 Adrenergic Antagonists Phase 3
28 Anti-Arrhythmia Agents Phase 3
29 Adrenergic beta-Antagonists Phase 3
30 Omega 3 Fatty Acid Phase 3
31 Emollients Phase 3
32
Selegiline Approved, Investigational, Vet_approved Phase 2 14611-51-9 26757 5195
33
Methylphenidate Approved, Investigational Phase 2 113-45-1 4158
34
Gemfibrozil Approved Phase 2 25812-30-0 3463
35
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
36
Tolcapone Approved, Withdrawn Phase 2 134308-13-7 4659569
37
Moxifloxacin Approved, Investigational Phase 2 354812-41-2, 151096-09-2 152946
38
Moclobemide Approved, Investigational Phase 2 71320-77-9 4235
39
Topiramate Approved Phase 2 97240-79-4 5284627
40
Zonisamide Approved, Investigational Phase 1, Phase 2 68291-97-4 5734
41
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
42
Aluminum sulfate Approved Phase 2 10043-01-3
43
Ondansetron Approved Phase 2 99614-02-5 4595
44
Glucagon Approved Phase 2 16941-32-5
45
Liraglutide Approved Phase 2 204656-20-2 44147092
46
Baclofen Approved Phase 2 1134-47-0 2284
47
Cycloserine Approved Phase 1, Phase 2 68-41-7 401 6234
48
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
49
Prazosin Approved Phase 2 19216-56-9 4893
50
Glycine Approved, Nutraceutical, Vet_approved Phase 2 56-40-6 750

Interventional clinical trials:

(show top 50) (show all 308)
# Name Status NCT ID Phase Drugs
1 Treatment of Smoking Lapses and Relapses Completed NCT01807871 Phase 4 nicotine patch, experimental use;nicotine patch, labeled use
2 Randomized Clinical Trial Comparing a Medication, i.e., Sustained-Release Bupropion (Zyban®) With an Ultrashort (1 1/2 d) Manual-Based Psychotherapeutic Intervention, Psychodynamic Model Training® Completed NCT00484692 Phase 4 sustained-release bupropion (Zyban(R))
3 Effectiveness of Bupropion Used in Combination With the Nicotine Replacement Patch and Cognitive Behavioral Therapy for Treating Nicotine Dependent Individuals - 1 Completed NCT00142831 Phase 4 Pharmacotherapies for Smoking Cessation
4 Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study Completed NCT00596882 Phase 4
5 Varenicline for Light Smokers Completed NCT01639560 Phase 4 Varenicline;Placebo
6 Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers Completed NCT02378714 Phase 4 Varenicline
7 The Long-Term Quitting Study: Testing Relapse Recovery Intervention Components Completed NCT02564315 Phase 4 Nicotine Mini-Lozenge for 11 Months;Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge
8 An Effectiveness Trial of Maintenance Therapy for Nicotine Dependence Completed NCT01047527 Phase 4 Transdermal nicotine patch
9 NRT & Bupropion Mechanisms of Effectiveness in Smokers: Phase IV Trial Completed NCT01048944 Phase 4 Bupropion SR;Nicotine Patch;Placebo Patch and Placebo Pill
10 Pharmacotherapies: Efficacy, Mechanisms and Algorithms Completed NCT00332644 Phase 4 nicotine patch;nicotine lozenge;nicotine patch + nicotine lozenge;bupropion;bupropion + lozenge;placebo
11 Effects of Intranasal Oxytocin on Cigarette Smoking Completed NCT02595749 Phase 4 Oxytocin;Placebo
12 Nicotine Replacement for Smoking Cessation During Pregnancy Completed NCT01656733 Phase 4 Nicotrol Inhaler;Placebo Inhaler
13 Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy Completed NCT01980550 Phase 4 sublingual nicotine
14 Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation Completed NCT02575183 Phase 4 Varinecline (Chantix);Placebo (for Varenicline)
15 Assessment of Smoking Topography and Behaviors During Response to Varenicline Completed NCT00948155 Phase 4 Varenicline
16 Validation of a Novel Paradigm for Screening Medications for Nicotine Dependence Completed NCT00948649 Phase 4 Placebo;Varenicline
17 Clinical Relevance of Stress Neuroadaptation in Tobacco Dependence Completed NCT03262233 Phase 4
18 Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging Completed NCT01664741 Phase 4 Nicotine patch - transdermal;placebo
19 Treatment of Nicotine Dependence and Acute Depression Completed NCT00186446 Phase 4 bupropion and smoking cessation behavioral intervention
20 Behavioral/Pharmacological Treatments for Alcohol-Nicotine Dependence Completed NCT00000447 Phase 4 naltrexone (Revia);nicotine replacement patch
21 Optimized Chronic Care for Smokers: Developing and Implementing Integrated Clinical and Systems Interventions in Primary Care - Cessation Trial Recruiting NCT04188873 Phase 4 Preparation Varenicline and Standard Duration Varenicline;Preparation Varenicline and Extended Duration Varenicline;Standard Duration Varenicline;Extended Duration Varenicline;Preparation Combination NRT and Standard Duration Combination NRT;Preparation Combination NRT and Extended Duration Combination NRT;Standard Duration Combination NRT;Extended Duration Combination NRT
22 Nicotine Replacement Therapy in Nicotine-dependent Arrestees: a Monocentric Randomized Simple Blind Study Active, not recruiting NCT02905734 Phase 4 Nicotine patch
23 Multimodal Imaging of Progesterone/Neurosteroid Effects in Nicotine Addiction Active, not recruiting NCT01954966 Phase 4 Progesterone;Placebo
24 A Placebo-Controlled, Randomized Trial of Eszopiclone for the Treatment of Bupropion- and Abstinence-Related Insomnia During Smoking Cessation Terminated NCT00511134 Phase 4 Eszopiclone;Bupropion
25 An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia Terminated NCT01576640 Phase 4 NRT;Bupropion SR 150mg bid
26 High-Dose Versus Regular-Dose Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder Terminated NCT00046813 Phase 4 Nicotine patch
27 Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia - a Double Blind, Placebo Controlled Trial Terminated NCT00727103 Phase 4 Varenicline;Placebo
28 Safety and Tolerability of Varenicline When Used for Smoking Cessation/Reduction in Individuals With Severe and Persistent Mental Illness: An Open Label Pilot Trial Withdrawn NCT00702793 Phase 4 Varenicline
29 Tailored Tobacco Intervention Unknown status NCT01892813 Phase 3 Nicotine replacement therapy - Transdermal nicotine patch;Nicotine replacement therapy - Nicotine gum;Nicotine replacement therapy - Nicotine lozenge;Bupropion;Varenicline;Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum;Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge;Combination pharmacotherapy - Transdermal nicotine patch + bupropion
30 Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy Completed NCT00067158 Phase 3 nicotine transdermal system
31 Naltrexone Augmentation of Nicotine Patch Therapy Completed NCT00218153 Phase 3 Naltrexone
32 Incentive Programs for Female Substance Abusers Who Smoke Completed NCT00064922 Phase 2, Phase 3
33 Smoking Treatment of Prisoners: Project "STOP" Completed NCT00110630 Phase 3
34 Smoking Cessation in Substance Abuse Treatment Patients: A Feasibility Study Completed NCT00408265 Phase 3
35 Tobacco Use in Opioid Agonist Treated Pregnant Women Completed NCT00497068 Phase 2, Phase 3
36 Maintaining Nonsmoking Completed NCT01162239 Phase 3 Varenicline
37 Extended Cessation Treatment for Teen Smokers Completed NCT00459953 Phase 2, Phase 3 Extended treatment
38 Smoking Treatment in HIV Clinical Care Settings Completed NCT00297453 Phase 3
39 Bupropion Treatment for Youth Smoking Cessation Completed NCT00344695 Phase 3 bupropion SR
40 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial Completed NCT01756885 Phase 3 Varenicline;Placebo
41 A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation Completed NCT01509547 Phase 3 Varenicline;placebo
42 Concurrent Bupropion / Varenicline for Smoking Cessation Completed NCT01303861 Phase 3 Varenicline;Bupropion;Nicotine patches;Nicotine Inhaler
43 Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation Completed NCT01406223 Phase 3 Varenicline;Bupropion;Nicotine patches
44 Examination of Sleep, Smoking Cessation, and Cardiovascular Health Completed NCT02941718 Phase 3
45 A Placebo Controlled Trial of Varenicline for Smoking Among Those With HIV/AIDS Completed NCT01710137 Phase 3 Varenicline;Placebo
46 Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence Completed NCT00749658 Phase 2, Phase 3 Bupropion;Varenicline
47 Using a YMCA Exercise Program to Enhance Nicotine Dependence Treatment for Women Completed NCT01615380 Phase 2, Phase 3
48 Memory Reconsolidation Blockade as a Novel Intervention for Nicotine Dependence Completed NCT00916721 Phase 3 Propranolol;Placebo
49 "Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence" Completed NCT01735279 Phase 3 Omega 3;Placebo
50 Testing Novel Pharmacogenetic and Adherence Optimization Treatments to Improve the Effectiveness of Smoking Cessation Treatments for Smokers With HIV Recruiting NCT04176172 Phase 3 Varenicline;Nicotine patch

Search NIH Clinical Center for Smoking As a Quantitative Trait Locus 3

Genetic Tests for Smoking As a Quantitative Trait Locus 3

Genetic tests related to Smoking As a Quantitative Trait Locus 3:

# Genetic test Affiliating Genes
1 Smoking As a Quantitative Trait Locus 3 29 CHRNA3 CHRNA5

Anatomical Context for Smoking As a Quantitative Trait Locus 3

MalaCards organs/tissues related to Smoking As a Quantitative Trait Locus 3:

40
Lung, Cortex, Skin, Brain, Endothelial, Amygdala, Prefrontal Cortex

Publications for Smoking As a Quantitative Trait Locus 3

Articles related to Smoking As a Quantitative Trait Locus 3:

(show top 50) (show all 5391)
# Title Authors PMID Year
1
A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. 61 6 57
18385739 2008
2
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. 6 57
18385676 2008
3
A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. 6 57
18385738 2008
4
Sequence variants at CHRNB3-CHRNA6 and CYP2A6 affect smoking behavior. 57 61
20418888 2010
5
Association of serum cotinine level with a cluster of three nicotinic acetylcholine receptor genes (CHRNA3/CHRNA5/CHRNB4) on chromosome 15. 61 57
19628476 2009
6
Risk for nicotine dependence and lung cancer is conferred by mRNA expression levels and amino acid change in CHRNA5. 61 6
19443489 2009
7
Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. 57 61
17135278 2007
8
Novel genes identified in a high-density genome wide association study for nicotine dependence. 57 61
17158188 2007
9
A genetically modulated, intrinsic cingulate circuit supports human nicotine addiction. 6
20643934 2010
10
Genome-wide meta-analyses identify multiple loci associated with smoking behavior. 57
20418890 2010
11
Meta-analysis and imputation refines the association of 15q25 with smoking quantity. 57
20418889 2010
12
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. 57
18978787 2008
13
Sexual orientation and gender identity disparities in co-occurring depressive symptoms and probable substance use disorders in a national cohort of young adults. 61
33626483 2021
14
Adolescence Predictors for Drug Crime Offending: A Follow-up Study of Former Adolescent Psychiatric Inpatients. 61
32910370 2021
15
Molecular genetics of substance use disorders: An umbrella review. 61
33556390 2021
16
Nicotine addiction: Translational insights from circuit neuroscience. 61
33727060 2021
17
[Effects of Motivational Interview and Mobile Social Network Support on Smoking Cessation in Male Patients With Coronary Heart Disease]. 61
33792019 2021
18
Harms of Electronic Cigarettes: What the Healthcare Provider Needs to Know. 61
33284731 2021
19
APOE genotype influences P3b amplitude and response to smoking abstinence in young adults. 61
33506304 2021
20
Detecting rare haplotype association with two correlated phenotypes of binary and continuous types. 61
33438281 2021
21
Preventing E-cigarette use among high-risk adolescents: A trauma-informed prevention approach. 61
33387976 2021
22
Nicotine Dependence and Stress Susceptibility in E-Cigarette Smokers: The Korea National Health and Nutrition Examination Survey 2013-2017. 61
33401344 2021
23
A longitudinal assessment of nicotine dependence, mental health, and attempts to quit Smoking: Evidence from waves 1-4 of the Population Assessment of Tobacco and Health (PATH) study. 61
33383566 2021
24
Vapers exhibit similar subjective nicotine dependence but lower nicotine reinforcing value compared to smokers. 61
33360443 2021
25
Relationship between "nomophobia" and material addiction "cigarette" and factors affecting them. 61
33159821 2021
26
Past-year discrimination and cigarette smoking among sexual minority women: investigating racial/ethnic and sexual identity differences. 61
33797683 2021
27
Dispositional gratitude and mental health in the U.S. veteran population: Results from the National Health and Resilience Veterans Study. 61
33516080 2021
28
Using machine learning to predict suicide in the 30 days after discharge from psychiatric hospital in Denmark. 61
33653425 2021
29
Financial strain and electronic nicotine delivery systems use among U.S. young adults: A longitudinal panel analysis, 2013-2018. 61
33109395 2021
30
The Impact of COVID-19 on Smoking Patterns in Pakistan: Findings From a Longitudinal Survey of Smokers. 61
33029618 2021
31
Predictive model of multiple emergency department visits among adults: analysis of the data from the National Survey of Drug Use and Health (NSDUH). 61
33766009 2021
32
Comparison of Interventional Methods to Motivate and Change the Behavioural Stage of Smokers to Quit Smoking- A Hospital Based Randomised Controlled Trial. 61
33773533 2021
33
Depressive Symptoms and Cigarette Smoking in Adolescents and Young Adults: Mediating Role of Friends Smoking. 61
33720376 2021
34
Behavioral Economic Demand for Alcohol and Cigarettes in Heavy Drinking Smokers: Evidence of Asymmetric Cross-commodity Reinforcing Value. 61
33247757 2021
35
Smoking-Specific Risk Factors in Early Adulthood That Mediate Risk of Daily Smoking by Age 29 for Children with ADHD. 61
33769107 2021
36
Association of Stress Management with Success of Smoking Cessation in Korean Female Emotional Labor Workers for Service and Sales. 61
33804218 2021
37
Impact of neuropsychological disorders on clinical aspects of smoking. 61
33768263 2021
38
Roma Socioeconomic Status Has a Higher Impact on Smoking Behaviour than Genetic Susceptibility. 61
33808833 2021
39
Care to Quit: a stepped wedge cluster randomised controlled trial to implement best practice smoking cessation care in cancer centres. 61
33663518 2021
40
Electronic Cigarettes and Their Impact on Allergic Respiratory Diseases: A Work Group Report of the AAAAI Environmental Exposures and Respiratory Health Committee. 61
33547027 2021
41
Gene-based association analysis reveals involvement of LAMA5 and cell adhesion pathways in nicotine dependence in African- and European-American samples. 61
32281736 2021
42
Model-based recursive partitioning of extended redundancy analysis with an application to nicotine dependence among US adults. 61
33782960 2021
43
Predicting smoking and nicotine dependence from the DSM-5 alternative model for personality pathology. 61
33705195 2021
44
SNPs within CHRNA5-A3-B4 and CYP2A6/B6, nicotine metabolite concentrations and nicotine dependence treatment success in smokers. 61
31796940 2021
45
Nicotine Dependence in Dual Users of Cigarettes and E-Cigarettes: Common and Distinct Elements. 61
33097952 2021
46
Haplotype-based association study of Opioid Receptor Kappa-type 1 (OPRK1) gene polymorphisms with nicotine dependence among male smokers. 61
32508243 2021
47
Nicotine dependence of cigarette and heated tobacco users in Japan, 2019: a cross-sectional analysis of the JASTIS Study. 61
33741741 2021
48
Genomic relationships across psychiatric disorders including substance use disorders. 61
33524898 2021
49
Attenuated and delayed niacin skin flushing in schizophrenia and affective disorders: A potential clinical auxiliary diagnostic marker. 61
33677199 2021
50
A multicentre tobacco cessation intervention study in the dental setting in Japan. 61
33743994 2021

Variations for Smoking As a Quantitative Trait Locus 3

ClinVar genetic disease variations for Smoking As a Quantitative Trait Locus 3:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CHRNA5 NM_000745.3(CHRNA5):c.1192G>A (p.Asp398Asn) SNV risk factor 17497 rs16969968 GRCh37: 15:78882925-78882925
GRCh38: 15:78590583-78590583
2 CHRNA5 NM_000745.3(CHRNA5):c.1192G>A (p.Asp398Asn) SNV risk factor 17497 rs16969968 GRCh37: 15:78882925-78882925
GRCh38: 15:78590583-78590583
3 CHRNA3 NM_000743.5(CHRNA3):c.645C>T (p.Tyr215=) SNV risk factor 17503 rs1051730 GRCh37: 15:78894339-78894339
GRCh38: 15:78601997-78601997
4 CHRNA3 NM_000743.5(CHRNA3):c.645C>T (p.Tyr215=) SNV risk factor 17503 rs1051730 GRCh37: 15:78894339-78894339
GRCh38: 15:78601997-78601997

Expression for Smoking As a Quantitative Trait Locus 3

Search GEO for disease gene expression data for Smoking As a Quantitative Trait Locus 3.

Pathways for Smoking As a Quantitative Trait Locus 3

GO Terms for Smoking As a Quantitative Trait Locus 3

Cellular components related to Smoking As a Quantitative Trait Locus 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.26 CHRNA5 CHRNA3
2 neuron projection GO:0043005 9.16 CHRNA5 CHRNA3
3 postsynaptic membrane GO:0045211 8.96 CHRNA5 CHRNA3
4 acetylcholine-gated channel complex GO:0005892 8.62 CHRNA5 CHRNA3

Biological processes related to Smoking As a Quantitative Trait Locus 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ion transport GO:0006811 9.43 CHRNA5 CHRNA3
2 ion transmembrane transport GO:0034220 9.4 CHRNA5 CHRNA3
3 chemical synaptic transmission GO:0007268 9.37 CHRNA5 CHRNA3
4 regulation of membrane potential GO:0042391 9.32 CHRNA5 CHRNA3
5 excitatory postsynaptic potential GO:0060079 9.26 CHRNA5 CHRNA3
6 nervous system process GO:0050877 9.16 CHRNA5 CHRNA3
7 synaptic transmission, cholinergic GO:0007271 8.96 CHRNA5 CHRNA3
8 behavioral response to nicotine GO:0035095 8.62 CHRNA5 CHRNA3

Molecular functions related to Smoking As a Quantitative Trait Locus 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane signaling receptor activity GO:0004888 9.4 CHRNA5 CHRNA3
2 ion channel activity GO:0005216 9.37 CHRNA5 CHRNA3
3 neurotransmitter receptor activity GO:0030594 9.32 CHRNA5 CHRNA3
4 extracellular ligand-gated ion channel activity GO:0005230 9.26 CHRNA5 CHRNA3
5 ligand-gated ion channel activity GO:0015276 9.16 CHRNA5 CHRNA3
6 acetylcholine-gated cation-selective channel activity GO:0022848 8.96 CHRNA5 CHRNA3
7 acetylcholine receptor activity GO:0015464 8.62 CHRNA5 CHRNA3

Sources for Smoking As a Quantitative Trait Locus 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....